External validation of precisebreast, a digital prognostic test for predicting breast cancer recurrence, in an early-stage cohort from the Netherlands.

ABSTRACT: Current clinical guidelines recommend gene expression profiling to guide treatment in early-stage breast cancer. PreciseBreast (PDxBR) is a digital prognostic tool that integrates artificial intelligence (AI)-derived features from hematoxylin and eosin (H&E) slides with clinicopathologic data to predict recurrence risk. This study externally validated PDxBR in an independent cohort and compared its performance to other risk models. We retrospectively analyzed PDxBR in a cohort of 739 patients with early-stage hormone receptor-positive, HER2-negative breast cancer (median follow-up of 8.8 years). For each case, one H&E-stained slide was digitized and analyzed to generate recurrence risk scores using the full PDxBR model, as well as image-only and clinical-only variants. A subset of patients

SUBMITTER: Westenend PJ 

PROVIDER: S-EPMC12369158 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature